Table 2.

Estimated Reporting Rate of All Malignancies and Lymphoma per 100 Patient-years (PY) of Etanercept Exposure

	4-17 years		18-22 years
	Worldwide	US	Worldwide	US
Estimated exposure to etanercept (PY) through July 2009	49,716	33,409	33,887	22,349
All malignancies (rate/100 PY)	0.020	0.015	0.024*	0.013*
Lymphoma (rate/100 PY)	0.010	0.009	0.006*	0.004*

*Calculated reporting rate for those age 18-22 years includes only cases with exposure prior to age 19 and does not includes cases with first etanercept exposure at age 19-22.